NEW YORK, July 18 – Ventana Medical Systems said Wednesday that GlaxoSmithKline has chosen its Discovery in situ hybridization and immunohistochemistry system for use in DNA and protein expression experiments.

GlaxoSmithKline will install six to eight of Ventana’s systems in its European and North American research facilities, Ventana CEO Christopher Gleeson told GenomeWeb. The two companies will also collaborate to develop improvements in tissue gene expression profiling methods.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.